Does sevoflurane cause uterine smooth muscle relaxation?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Yes, sevoflurane causes uterine smooth muscle relaxation and may contribute to uterine atony.

Sevoflurane directly relaxes uterine smooth muscle in a dose-dependent manner, which is explicitly stated in the FDA drug label and confirmed by multiple research studies. 1

Mechanism and Clinical Evidence

The FDA label for sevoflurane clearly states: "Sevoflurane can cause uterine smooth muscle relaxation and may contribute to uterine atony" 1. This is a critical warning for obstetric use, particularly during cesarean delivery where uterine tone is essential for hemostasis after placental delivery.

Dose-Dependent Effects

Research demonstrates that sevoflurane produces concentration-dependent depression of uterine contractility:

  • ED50 (50% inhibition) occurs at approximately 0.94-1.72 MAC 2, 3
  • At 3.5 MAC and above, uterine activity is virtually abolished 3
  • Both amplitude and frequency of contractions are reduced 4, 5

Mechanism of Action

The relaxation occurs through multiple pathways:

  • Inhibition of voltage-dependent calcium channels (VDCCs), reducing intracellular calcium concentration 5
  • Activation of calcium-activated potassium (K+) channels, which was demonstrated when the effect was partially reversed by tetraethylammonium (a K+ channel blocker) 4
  • Direct depression of myometrial contractility comparable to other volatile anesthetics like halothane and isoflurane 2, 5

Clinical Implications for Obstetric Anesthesia

When Sevoflurane is Used

According to current obstetric anesthesia guidelines, sevoflurane is usually restricted to patients with a secured airway during cesarean delivery 6. It may be used as supplemental inhalational medication for pain management during cesarean delivery under neuraxial anesthesia, but this application is limited.

Special Circumstances

For open fetal surgery requiring complete uterine relaxation, volatile anesthetics including sevoflurane are intentionally used for this muscle-relaxing property 7. However, high doses can lead to fetal cardiovascular depression.

Critical Caveat

The uterine relaxation effect is both therapeutic and dangerous:

  • Therapeutic: When uterine relaxation is needed (difficult deliveries, fetal surgery)
  • Dangerous: Risk of postpartum hemorrhage from uterine atony after delivery

Clinicians must be prepared to manage uterine atony with uterotonics (oxytocin, methylergonovine, carboprost) if sevoflurane has been used during cesarean delivery. The relaxation effect is reversible once the anesthetic is discontinued, but the immediate postpartum period requires vigilant monitoring for adequate uterine tone.

Comparison to Other Anesthetics

Sevoflurane's inhibitory potency on uterine muscle is comparable to halothane and desflurane, but greater than isoflurane 2. All volatile anesthetics share this property, making it a class effect rather than unique to sevoflurane.

Human myometrial studies confirm these effects occur in pregnant human tissue, not just animal models 2, 3, making this clinically relevant and directly applicable to obstetric practice.

References

3
Research

The effects of sevoflurane on isolated gravid human myometrium.

Anaesthesia and intensive care, 2002

6
Guideline

neuraxial anesthesia and pain management for cesarean delivery.

American Journal of Obstetrics and Gynecology, 2026

Related Questions

What are the indications, dosing regimen, contraindications, adverse effects, and counseling considerations for flibanserin in premenopausal women with acquired generalized hypoactive sexual desire disorder?
What are the optimal nutrition and supplement recommendations for weight loss in a generally healthy menopausal woman?
Given an anion gap of 21 mEq/L, a bicarbonate of 19 mEq/L, and a ketone level of 1.56 mmol/L, does this indicate diabetic ketoacidosis?
What 5‑HT2A antagonists are appropriate for a premenopausal woman with acquired generalized hypoactive sexual desire disorder, and what are their dosing and safety considerations?
Can diabetic ketoacidosis (DKA) be diagnosed when β‑hydroxybutyrate (BHB) is only about 1.5 mmol/L, given an elevated anion gap and low bicarbonate?
In a premenopausal woman with acquired generalized hypoactive sexual desire disorder, can buspirone (a 5‑HT1A partial agonist) be used as a first‑line or approved therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.